Cardiff Oncology to Present at the H.C. Wainwright BioConnect Virtual Conference
Cardiff Oncology (Nasdaq: CRDF) announced its participation at the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Cardiff Oncology (Nasdaq: CRDF) announced its participation at the H.C. Wainwright BioConnect Virtual Conference from January 10 to 13, 2022. The presentation will be available on-demand starting at 7:00 AM ET on January 10. Cardiff Oncology focuses on developing precision medicine for cancer patients, specifically targeting KRAS-mutated colorectal cancer, pancreatic cancer, and castrate-resistant prostate cancer. Their investigational drug, onvansertib, is a third-generation Polo-like Kinase 1 inhibitor designed to improve treatment responses and overall survival.
Details
News Market Reaction – CRDF
The recorded move for CRDF in the trading session of this news was -2.18%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Jan. 4, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology company, developing new precision medicine treatment options for cancer patients in indications with the greatest unmet medical need including KRAS-mutated colorectal cancer, pancreatic cancer, and castrate-resistant prostate cancer, today announced that company management will present at the H.C. Wainwright BioConnect Virtual Conference, taking place January 10 – 13, 2022.
Details on the presentation can be found below.
H.C. Wainwright BioConnect Virtual Conference | |
Presentation Date: | Available on-demand beginning at 7:00 AM ET on Monday, January 10, 2022 |
A webcast of the presentation will be available on the "Events" section of the Cardiff Oncology website.
About Cardiff Oncology, Inc.
Cardiff Oncology is a clinical-stage oncology company, developing new precision medicine treatment options for cancer patients in indications with the greatest unmet medical need. Our goal is to target tumor vulnerabilities with treatment combinations that overcome disease resistance and improve disease response to standard treatment regimens and to increase overall survival. We are developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 ("PLK1") inhibitor, in combination with standard-of-care anti-cancer therapeutics. Our clinical development programs incorporate tumor genomics and biomarker technology to refine assessment of patient response to treatment. We have three clinical programs currently ongoing: a Phase 1b/2 study of onvansertib in combination with FOLFIRI/Avastin® (bevacizumab) in KRAS-mutated metastatic colorectal cancer (mCRC); a Phase 2 trial of onvansertib in combination with nanoliposomal irinotecan, leucovorin and fluorouracil for the second-line treatment of patients with metastatic pancreatic ductal adenocarcinoma (PDAC); and a Phase 2 study of onvansertib in combination with Zytiga® (abiraterone)/prednisone in metastatic castrate-resistant prostate cancer (mCRPC). For more information, please visit https://www.cardiffoncology.com.
Cardiff Oncology Contact:
Vicki Kelemen
Chief Operating Officer
858-952-7652
vkelemen@cardiffoncology.com
Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com
Media Contact:
Amy Jobe, Ph.D.
LifeSci Communications
315-879-8192
ajobe@lifescicomms.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/cardiff-oncology-to-present-at-the-hc-wainwright-bioconnect-virtual-conference-301453253.html
SOURCE Cardiff Oncology, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.